Mitochondrial-dependent oxidative phosphorylation is key for postnatal metabolic adaptation of alveolar macrophages in the lung
Int Immunopharmacol. 2024 Apr 23;133:112012. doi: 10.1016/j.intimp.2024.112012. Online ahead of print.ABSTRACTAlveolar macrophages (AMs) seed in lung during embryogenesis and become mature in perinatal period. Establishment of acclimatization to environmental challenges is important, whereas the detailed mechanisms that drive metabolic adaptation of AMs remains to be elucidated. Here, we showed that energy metabolism of AMs was transformed from glycolysis prenatally to oxidative phosphorylation (OXPHOS) postnatally accompanied by up-regulated expression of mitochondrial transcription factor A (TFAM). TFAM deficiency distur...
Source: International Immunopharmacology - April 24, 2024 Category: Allergy & Immunology Authors: Jun Zhang Yu Peng Haosen Song Siqi Liu Chuanwei Li Yi Zhang Xiaowei Shi Huifang Guo Yingping Xu Source Type: research
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
CONCLUSION: Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.PMID:38658461 | DOI:10.1007/s12094-024-03491-8 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 24, 2024 Category: Cancer & Oncology Authors: V ítor Silva Cristiano Matos Source Type: research
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
CONCLUSION: Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.PMID:38658461 | DOI:10.1007/s12094-024-03491-8 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: V ítor Silva Cristiano Matos Source Type: research
Comprehensive genetic profiling reveals frequent alterations of driver genes on the X chromosome in extranodal NK/T-cell lymphoma
Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-24-0132. Online ahead of print.ABSTRACTExtranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm with male dominance and a poor prognosis. A better understanding of the genetic alterations and their functional roles in ENKTCL could help improve patient stratification and treatments. Here, we performed comprehensive genetic analysis of 177 ENKTCL cases to delineate the landscape of mutations, copy number alterations (CNAs), and structural variations, identifying 34 driver genes including six previously unappreciated ones, namely HLA-B, HLA-C, R...
Source: Cell Research - April 24, 2024 Category: Cytology Authors: Yuta Ito Amira Marouf Yasunori Kogure Junji Koya Rapha ël Liévin Julie Bruneau Mariko Tabata Yuki Saito Sumito Shingaki Mitsuhiro Yuasa Kentaro Yamaguchi Koichi Murakami Robert Weil Manon Vavasseur Guillaume P Andrieu Mehdi Latiri Layla Veleanu Micha ë Source Type: research
GSE263183 Transcriptomic changes in SUDHL6 cells upon treatment with S63845 in the presence or abscence of active caspases
Contributor : Meike VoglerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe identified a novel form of caspase-independent cell death (CICD) induced by BH3-mimetics. To characterize the transcriptional changes during CICD and compare these to apoptotic changes, we performed RNA Seq analysis on SUDHL6 lymphoma cells treated with the MCL1 inhibitor S63845 in the presence or abscence of the broad spectrum caspase inhibitor zVAD.fmk. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE243973 Circulating monocyte counts coupled with a 4-gene signature at leukapheresis predict survival of lymphoma patients treated with CAR T
Contributors : Cristiana Carniti ; Nicole Caldarelli ; Luca Agnelli ; Tommaso Torelli ; Silva Ljevar ; Sadhana Jonnalagadda ; Giada Zanirato ; Eugenio Fardella ; Daniele Lorenzini ; Silvia Brich ; Anna Dodero ; Annalisa Chiappella ; Martina Magni ; Paolo CorradiniSeries Type : Expression profiling by arrayOrganism : Homo sapiensCD19-directed chimeric antigen receptor (CAR) T cells can induce durable remissions in relapsed/refractory large B-cell lymphomas (R/R LBCL), but 60% of patients still relapse. Biological mechanisms explaining lack of disease-response are largely unknown. To identify mechanisms of res...
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
GSE185841 SUMOylation inhibitor TAK-981 potentiates rituximab activity by Type I IFN-dependent macrophage and NK cell stimulation
In this report, we have explored the activity of the selective small molecule SUMOylation inhibitor TAK-981 in promoting antitumor innate immune responses. We demonstrate that treatment with TAK-981 results in IFN1-dependent macrophage and NK cell activation, promoting macrophage phagocytosis and NK cell cytotoxicity in ex vivo assays. Furthermore, pre-treatment with TAK-981 enhanced macrophage phagocytosis or NK cell cytotoxicity against CD20-positive target cells in combination with the anti-CD20 antibody rituximab. In vivo studies demonstrated synergistic antitumor activity of TAK-981 and rituximab in CD20-positive lymp...
Source: GEO: Gene Expression Omnibus - April 24, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 24, 2024 Category: Hematology Source Type: research
Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 24, 2024 Category: Hematology Source Type: research
Molecules, Vol. 29, Pages 1956: In Vivo, In Vitro and In Silico Anticancer Activity of Ilama Leaves: An Edible and Medicinal Plant in Mexico
This study provides information that supports the anticancer potential of geranylgeraniol, phytol and farnesyl acetate as compounds for the treatment of cancer, particularly with the potential to treat non-Hodgkin’s lymphoma. (Source: Molecules)
Source: Molecules - April 24, 2024 Category: Chemistry Authors: Ram írez-Santos Calzada Ordo ñez-Razo Mendieta-Wejebe Vel ázquez-Domínguez Arg üello-García Vel ázquez Barbosa Tags: Article Source Type: research
Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Opinion StatementDiffuse large B-cell lymphoma (DLBCL) is a curable disease with variable outcomes due to underlying heterogeneous clinical and molecular features —features that are insufficiently characterized with our current tools. Due to these limitations, treatment largely remains a “one-size-fits-all” approach. Circulating tumor DNA (ctDNA) is a novel biomarker in cancers that is increasingly utilized for risk stratification and response assessmen t. ctDNA is readily detectable from the plasma of patients with DLBCL but has not yet been incorporated into clinical care to guide treatment. Here, we describe how c...
Source: Current Treatment Options in Oncology - April 24, 2024 Category: Cancer & Oncology Source Type: research
Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution
CONCLUSION: This study provides an overview of the clinical impact of CMV reactivation in patients with PCD treated with anti-CD38 mAb-containing regimens.PMID:38653670 | DOI:10.1016/j.clml.2024.03.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 23, 2024 Category: Cancer & Oncology Authors: Naohiro Matsunaga Tomotaka Suzuki Nozomi Nishitarumizu Yoko Nakanishi Aki Kondo Yukiyasu Kato Toru Ebina Yoshiaki Marumo Tomoyuki Nakamura Takahiro Nakashima Shiori Kinoshita Tomoko Narita Masaki Ri Shigeru Kusumoto Hirokazu Komatsu Shinsuke Iida Source Type: research
Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5 < sup > + < /sup > diffuse large-B cell lymphoma
J Chemother. 2024 Apr 23:1-9. doi: 10.1080/1120009X.2024.2340147. Online ahead of print.ABSTRACTCD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and ni...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Yosuke Masamoto Akira Honda Aya Shinozaki-Ushiku Tetsuo Ushiku Mineo Kurokawa Source Type: research
Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas
CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.PMID:38653368 | DOI:10.1016/j.ad.2024.04.017 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 23, 2024 Category: Dermatology Authors: R Izu-Belloso I Gainza-Apraiz P Ortiz-Romero O Servitje-Bedate R Fern ández de Misa-Cabrera Y Pe ñate-Santana B Hernandez-Machin T Estrach-Panella M Llamas-Velasco J I Yanguas-Bayona M Morillo-Andujar E Acebo-Mari ñas S Perez-Gala J C Armario-Hita P Sa Source Type: research
Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects
Cell Transplant. 2024 Jan-Dec;33:9636897241247951. doi: 10.1177/09636897241247951.ABSTRACTHematological toxicity is a severe adverse event (AE) in anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the pathophysiological mechanism underlying prolonged cytopenia and the relationship between persistent cytopenia, efficacy, and AEs after anti-CD19 CAR T cell therapy are unknown. Therefore, this study explored whether persistent cytopenia after anti-CD19 CAR T cell therapy in patients with R/R DLBCL can predict therapeutic efficacy and AEs. Thi...
Source: Cell Transplantation - April 23, 2024 Category: Cytology Authors: Jingyi Li Juan Mu Jia Wang Xin Li Qing Li Yili Jiang Rui Cui Qi Deng Source Type: research
